Estradiol Patent Expiration
Estradiol was first introduced by Novartis Pharmaceuticals Corp
Estradiol Patents
Given below is the list of patents protecting Estradiol, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Imvexxy | US11266661 | Vaginal inserted estradiol pharmaceutical compositions and methods | Feb 02, 2034 | Mayne Pharma |
Imvexxy | US10258630 | Vaginal inserted estradiol pharmaceutical compositions and methods | Dec 20, 2033 | Mayne Pharma |
Imvexxy | US10398708 | Vaginal inserted estradiol pharmaceutical compositions and methods | Dec 20, 2033 | Mayne Pharma |
Imvexxy | US9180091 | Soluble estradiol capsule for vaginal insertion | Dec 20, 2033 | Mayne Pharma |
Imvexxy | US10471072 | Vaginal inserted estradiol pharmaceutical compositions and methods | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US10568891 | Vaginal inserted estradiol pharmaceutical compositions and methods | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US10668082 | Vaginal inserted estradiol pharmaceutical compositions and methods | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US10888516 | Soluble estradiol capsule for vaginal insertion | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US11065197 | Soluble estradiol capsule for vaginal insertion | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US11116717 | Soluble estradiol capsule for vaginal insertion | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US11123283 | Soluble estradiol capsule for vaginal insertion | Jun 18, 2033 | Mayne Pharma |
Imvexxy | US10537581 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US10806697 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US10835487 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US11241445 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US11246875 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US11304959 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US11351182 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US11497709 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Imvexxy | US9289382 | Vaginal inserted estradiol pharmaceutical compositions and methods | Nov 21, 2032 | Mayne Pharma |
Minivelle | US8231906 | Transdermal estrogen device and delivery | Jul 04, 2030 | Noven |
Minivelle | US9724310 | Transdermal estrogen device and delivery | Jul 10, 2028 | Noven |
Minivelle | US9730900 | Transdermal estrogen device and delivery | Jul 10, 2028 | Noven |
Minivelle | US9833419 | Transdermal estrogen device and delivery | Jul 10, 2028 | Noven |
Vagifem | US7018992 | Hormone composition |
Sep 17, 2022
(Expired) | Novo Nordisk Inc |
Elestrin | US7198801 | Formulations for transdermal or transmucosal application |
Jun 25, 2022
(Expired) | Mylan Speciality Lp |
Evamist | US6978945 | Dispensing device |
Nov 30, 2021
(Expired) | Padagis Us |
Elestrin | US7470433 | Formulations for transdermal or transmucosal application |
Aug 03, 2021
(Expired) | Mylan Speciality Lp |
Minivelle | US6841716 | Patch |
Apr 27, 2020
(Expired) | Noven |
Menostar | US5891868 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Nov 21, 2017
(Expired) | Bayer Hlthcare |
Menostar | US6692763 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Nov 21, 2017
(Expired) | Bayer Hlthcare |
Vagifem | US5860946 | Instrument for inserting a suppository |
Jul 01, 2017
(Expired) | Novo Nordisk Inc |
Evamist | US6299900 | Dermal penetration enhancers and drug delivery systems involving same |
Feb 19, 2017
(Expired) | Padagis Us |
Evamist | US6818226 | Dermal penetration enhancers and drug delivery systems involving same |
Feb 19, 2017
(Expired) | Padagis Us |
Evamist | US6923983 | Transdermal delivery of hormones |
Feb 19, 2017
(Expired) | Padagis Us |
Minivelle | US5646286 | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines |
Aug 12, 2014
(Expired) | Noven |
Minivelle | US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug 12, 2014
(Expired) | Noven |
Vivelle-dot | US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Aug 12, 2014
(Expired) | Sandoz |
Minivelle | US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan 07, 2014
(Expired) | Noven |
Vivelle-dot | US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Jan 07, 2014
(Expired) | Sandoz |
Vivelle-dot | US5474783 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec 12, 2012
(Expired) | Sandoz |
Vivelle-dot | US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec 12, 2012
(Expired) | Sandoz |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Estradiol's patents.
Latest Legal Activities on Estradiol's Patents
Given below is the list recent legal activities going on the following patents of Estradiol.
Activity | Date | Patent Number |
---|---|---|
Patent Issue Date Used in PTA Calculation Critical | 28 Mar, 2006 | US7018992 |
Recordation of Patent Grant Mailed Critical | 28 Mar, 2006 | US7018992 |
Issue Notification Mailed Critical | 08 Mar, 2006 | US7018992 |
Receipt into Pubs | 23 Feb, 2006 | US7018992 |
Dispatch to FDC | 22 Feb, 2006 | US7018992 |
Application Is Considered Ready for Issue Critical | 22 Feb, 2006 | US7018992 |
Receipt into Pubs | 20 Jan, 2006 | US7018992 |
Printer Rush- No mailing | 27 Sep, 2005 | US7018992 |
Pubs Case Remand to TC Critical | 06 Sep, 2005 | US7018992 |
Workflow - File Sent to Contractor | 03 Jun, 2005 | US7018992 |
Estradiol's Family Patents
Explore Our Curated Drug Screens
Estradiol Generic API Manufacturers
Several generic applications have been filed for Estradiol. The first generic version for Estradiol was by Bristol Myers Squibb Co Pharmaceutical Research Institute and was approved on Approved Prior to Jan 1, 1982. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Aug 2, 2024.
Given below is the list of companies who have filed for Estradiol generic, along with the locations of their manufacturing plants worldwide..
1. ALLERGAN
Allergan Sales Llc has filed for 1 generic for Estradiol. This 0.01% version comes by the name ESTRACE. Given below are the details of the strengths of this generic introduced by Allergan.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.01%
(reference standard) (reference listed drug) | cream | Prescription | VAGINAL | AB | Jan 31, 1984 |
Manufacturing Plant Locations New
Allergan's manufacturing plants are situated in 4 countries - United States, Costa Rica, France, Ireland. Given below are the details of these plant locations as well as the firm names of Allergan as present at those locations.
Country | City | Firm Name | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||
Costa Rica |
| |||||||||||||
France |
| |||||||||||||
Ireland |
|
2. ALVOGEN
Alvogen Inc has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Alvogen.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.01% | cream | Prescription | VAGINAL | AB | Mar 5, 2018 |
Manufacturing Plant Locations New
Alvogen's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Alvogen as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
3. AMNEAL
Amneal Pharmaceuticals Llc has filed for 10 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Amneal.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Sep 28, 2020 |
0.075MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Sep 28, 2020 |
0.1MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Sep 28, 2020 |
0.0375MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Sep 28, 2020 |
0.025MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Sep 28, 2020 |
0.1% (1.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (1GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (0.75GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (0.5GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (0.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||
India |
|
4. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MCG | tablet | Prescription | VAGINAL | AB | May 29, 2015 |
5. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MCG | tablet | Prescription | VAGINAL | AB | Aug 2, 2024 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
India |
| |||||||||
United States |
|
6. BARR LABS INC
Barr Laboratories Inc has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Barr Labs Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.5MG | tablet | Prescription | ORAL | AB | Oct 22, 1997 |
1MG | tablet | Prescription | ORAL | AB | Oct 22, 1997 |
2MG
(reference standard) | tablet | Prescription | ORAL | AB | Oct 22, 1997 |
7. BRISTOL MYERS SQUIBB
Bristol Myers Squibb Co has filed for 3 different strengths of generic version for Estradiol. All of these versions come by the name ESTRACE. Given below are the details of the strengths of this generic introduced by Bristol Myers Squibb.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG
(reference listed drug) | tablet | Discontinued | ORAL | N/A | Approved Prior to Jan 1, 1982 |
2MG
(reference listed drug) | tablet | Discontinued | ORAL | N/A | Approved Prior to Jan 1, 1982 |
0.5MG | tablet | Discontinued | ORAL | N/A | Jun 30, 1993 |
Manufacturing Plant Locations New
Bristol Myers Squibb's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Bristol Myers Squibb as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
United States |
|
8. CHEMO RESEARCH SL
Chemo Research Sl has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Chemo Research Sl.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.1% (1GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 10, 2022 |
0.1% (0.5GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 10, 2022 |
0.1% (0.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 10, 2022 |
9. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.5MG | tablet | Discontinued | ORAL | N/A | Mar 14, 1996 |
1MG | tablet | Discontinued | ORAL | N/A | Mar 14, 1996 |
2MG | tablet | Discontinued | ORAL | N/A | Mar 14, 1996 |
10. DURAMED PHARMS BARR
Duramed Pharmaceuticals Inc Sub Barr Laboratories Inc has filed for 4 different strengths of generic version for Estradiol. All of these versions come by the name GYNODIOL. Given below are the details of the strengths of this generic introduced by Duramed Pharms Barr.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.5MG | tablet | Discontinued | ORAL | N/A | Dec 29, 1997 |
1MG | tablet | Discontinued | ORAL | N/A | Dec 29, 1997 |
1.5MG | tablet | Discontinued | ORAL | N/A | Dec 29, 1997 |
2MG | tablet | Discontinued | ORAL | N/A | Dec 29, 1997 |
11. EPIC PHARMA LLC
Epic Pharma Llc has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Epic Pharma Llc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG | tablet | Prescription | ORAL | AB | Dec 29, 1998 |
0.5MG | tablet | Prescription | ORAL | AB | Dec 29, 1998 |
2MG | tablet | Prescription | ORAL | AB | Dec 29, 1998 |
12. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MCG | tablet | Prescription | VAGINAL | AB | Sep 14, 2018 |
13. LANNETT CO INC
Lannett Co Inc has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG | tablet | Discontinued | ORAL | N/A | Jan 30, 1998 |
0.5MG | tablet | Discontinued | ORAL | N/A | Jan 30, 1998 |
2MG | tablet | Discontinued | ORAL | N/A | Jan 30, 1998 |
14. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Mylan.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.01% | cream | Prescription | VAGINAL | AB | Dec 29, 2017 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||
India |
| |||||||||||||||||
Canada |
| |||||||||||||||||
Ireland |
|
15. MYLAN TECHNOLOGIES
Mylan Technologies Inc has filed for 6 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Mylan Technologies.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.05MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Aug 15, 2018 |
0.1MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Aug 15, 2018 |
0.075MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Aug 15, 2018 |
0.025MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Aug 15, 2018 |
0.0375MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB3 | Aug 15, 2018 |
0.06MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB | Jul 20, 2006 |
Manufacturing Plant Locations New
Mylan Technologies's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Mylan Technologies as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
16. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG | tablet | Discontinued | ORAL | N/A | Apr 21, 1999 |
2MG | tablet | Discontinued | ORAL | N/A | Apr 21, 1999 |
0.5MG | tablet | Discontinued | ORAL | N/A | Apr 21, 1999 |
17. NOVITIUM PHARMA
Novitium Pharma Llc has filed for 8 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Novitium Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.1% (1.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 24, 2023 |
0.1% (1GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 24, 2023 |
0.1% (0.75GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 24, 2023 |
0.1% (0.5GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 24, 2023 |
0.1% (0.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Aug 24, 2023 |
2MG | tablet | Prescription | ORAL | AB | Sep 6, 2023 |
0.5MG | tablet | Prescription | ORAL | AB | Sep 6, 2023 |
1MG | tablet | Prescription | ORAL | AB | Sep 6, 2023 |
Manufacturing Plant Locations New
Novitium Pharma's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Novitium Pharma as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
18. NOVO NORDISK INC
Novo Nordisk Inc has filed for 3 different strengths of generic version for Estradiol. All of these versions come by the name INNOFEM. Given below are the details of the strengths of this generic introduced by Novo Nordisk Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
1MG | tablet | Discontinued | ORAL | N/A | Nov 19, 1999 |
2MG | tablet | Discontinued | ORAL | N/A | Nov 19, 1999 |
0.5MG | tablet | Discontinued | ORAL | N/A | Nov 19, 1999 |
Manufacturing Plant Locations New
Novo Nordisk Inc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Novo Nordisk Inc as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
19. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Padagis Israel.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.01% | cream | Prescription | VAGINAL | AB | Jan 22, 2018 |
0.1% (0.75GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Nov 14, 2023 |
0.1% (1GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Nov 14, 2023 |
0.1% (1.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Nov 14, 2023 |
0.1% (0.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Nov 14, 2023 |
0.1% (0.5GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Nov 14, 2023 |
Manufacturing Plant Locations New
Padagis Israel's manufacturing plants are situated in 1 country - Israel. Given below are the details of these plant locations as well as the firm names of Padagis Israel as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
Israel |
|
20. PRASCO
Prasco Llc Dba Prasco Laboratories has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Prasco.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.01% | cream | Prescription | VAGINAL | AB | Jul 15, 2021 |
Manufacturing Plant Locations New
Prasco's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Prasco as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
21. QUAGEN
Quagen Pharmaceuticals Llc has filed for 5 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Quagen.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.1% (0.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (0.5GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (0.75GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (1GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
0.1% (1.25GM/PACKET) | gel | Prescription | TRANSDERMAL | AB | Jul 12, 2024 |
Manufacturing Plant Locations New
Quagen's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Quagen as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
United States |
|
22. SOLARIS PHARMA CORP
Solaris Pharma Corp has filed for 1 generic for Estradiol. Given below are the details of the strengths of this generic introduced by Solaris Pharma Corp.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.06% (1.25GM/ACTIVATION) | gel, metered | Prescription | TRANSDERMAL | AB | Apr 22, 2024 |
Manufacturing Plant Locations New
Solaris Pharma Corp's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Solaris Pharma Corp as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
23. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MCG | tablet | Prescription | VAGINAL | AB | Jul 21, 2017 |
0.01% | cream | Prescription | VAGINAL | AB | Mar 30, 2018 |
24. USL PHARMA
Usl Pharma Inc has filed for 3 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Usl Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.5MG | tablet | Discontinued | ORAL | N/A | Apr 17, 2002 |
2MG | tablet | Discontinued | ORAL | N/A | Apr 17, 2002 |
1MG | tablet | Discontinued | ORAL | N/A | Apr 17, 2002 |
25. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 7 different strengths of generic version for Estradiol. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.1MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB2 | Mar 29, 2023 |
0.075MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB2 | Mar 29, 2023 |
0.05MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB2 | Mar 29, 2023 |
0.0375MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB2 | Mar 29, 2023 |
0.025MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB2 | Mar 29, 2023 |
0.06MG/24HR | film, extended release | Prescription | TRANSDERMAL | AB2 | Mar 29, 2023 |
0.014MG/24HR | system | Prescription | TRANSDERMAL | AB | Apr 17, 2023 |